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Hereditary sensory and autonomic neuropathy (HSAN) type II is an autosomal recessive disorder characterized by
impairment of pain, temperature, and touch sensation owing to reduction or absence of peripheral sensory neurons.
We identified two large pedigrees segregating the disorder in an isolated population living in Newfoundland and
performed a 5-cM genome scan. Linkage analysis identified a locus mapping to 12p13.33 with a maximum LOD
score of 8.4. Haplotype sharing defined a candidate interval of 1.06 Mb containing all or part of seven annotated
genes, sequencing of which failed to detect causative mutations. Comparative genomics revealed a conserved ORF
corresponding to a novel gene in which we found three different truncating mutations among five families including
patients from rural Quebec and Nova Scotia. This gene, termed “HSN2,” consists of a single exon located within
intron 8 of the PRKWNK1 gene and is transcribed from the same strand. The HSN2 protein may play a role in
the development and/or maintenance of peripheral sensory neurons or their supporting Schwann cells.
The hereditary sensory and autonomic neuropathies
(HSANs) comprise at minimum a group of five clinically
heterogeneous disorders, characterized by variable sen-
sory and autonomic dysfunction due to peripheral nerve
degeneration (Dyck 1993; Axelrod 2002; Hilz 2002).
HSANs are distinct from the more prevalent motor and
sensory neuropathies (Charcot-Marie-Tooth disorders)
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because sensory involvement is primary. Moreover, the
abnormalities of autonomic function and varying de-
grees of analgesia are specific to the HSANs (Axelrod
2002).
Mutations have previously been identified for auto-
somal dominant, adult-onset HSAN type I (MIM
162400) (Bejaoui et al. 2001; Dawkins et al. 2001); for
autosomal recessive HSAN type III, also known as
“familial dysautonomia/Riley Day syndrome” (MIM
223900) (Anderson et al. 2001; Slaugenhaupt et al.
2001); and for autosomal recessive HSAN type IV, also
called “congenital insensitivity to pain with anhidrosis”
(MIM 256800) (Mardy et al. 1999). HSAN type V is
the least reported of the five disorders and remains some-
what uncertain in phenotypic description and molecular
basis (Houlden et al. 2001; Toscano et al. 2002; Axelrod
2002; Hilz 2002; Einarsdottir et al. 2004). Recently, a
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rare subtype of HSAN type I (type IB) with cough and
gastroesophageal reflux has been described and mapped
to a novel locus (MIM 608088) (Kok et al. 2003).
Locus identification has not yet been described for the
autosomal recessive HSAN type II (MIM 201300), also
called “neurogenic acroosteolysis,” “hereditary sensory
radicular neuropathy,” or “congenital sensory neurop-
athy.” Clinical description of HSAN type II in the lit-
erature is not completely consistent; however, diagnosis
can be made on the basis of natural history, a group of
clinical findings, and pathology (Axelrod 2002). HSAN
type II is generally defined by progressive degeneration
of peripheral neurons, typically with onset in the first 2
decades, manifesting sensory reduction in the upper and
lower limbs (Ogryzlo 1946; Murray 1973; Ohta et al.
1973; Kondo and Horikawa 1974). There have been
reports of a nonprogressive, stable congenital form of
HSAN type II with neonatal hypotonia and sensory im-
pairment affecting the whole body rather than just the
limbs, suggesting two different clinical subtypes of the
type II disease (Ferriere et al. 1992). The worldwide
prevalence of HSAN type II is low, but clustering of cases
in eastern Canada has been reported (Murray 1973;
Roddier et al. 2003).
HSAN type II in Newfoundland was first noted in the
early 1900s. The original family members came from
Dorset, United Kingdom, ∼100 years earlier, as part of
a mass migration of Protestant settlers from southwest-
ern England and Roman Catholic settlers from southern
Ireland (Rahman et al. 2003). The affected individuals
ascertained in this study had the following clinical fea-
tures: Beginning in early childhood, they experienced
numbness in their hands and feet, aggravated by cold,
together with reduced sensation to pain. They experi-
enced loss of touch, pain, and temperature, with touch
most severely affected. The loss was predominantly dis-
tal, extending from the elbows to the finger tips and
from just above the knees down to the toes. This is often
described as the “glove and sock distribution.” Typically,
the lower limbs were affected more severely than the
upper limbs. Progression of the disorder varied within
the family, however, involving the trunk in some pa-
tients. In some cases, secondary features of muscle at-
rophy, diminished tendon reflexes, ulcerations, and in-
fections caused spontaneous amputation of digits and
surgical amputation of lower limbs (fig. 1a). Patients did
not express any overt autonomic dysfunction. Sweating
and tearing were within normal range, and postural hy-
potension was not present. Mental development was
normal. As in the other HSANs, there was absence of
axon flare after intradermal histamine, indicative of de-
fective nociceptive fibers. Biopsy revealed a severe loss
of myelinated axons, some loss of nonmyelinated fibres
in the sural nerve, and the absence of cutaneous sensory
receptors and nerve fibers.
To identify the HSAN II locus, we expanded a con-
sanguineous multigenerational family (F1) with eight af-
fected members, living or deceased, from the Newfound-
land sibship reported previously (Ogryzlo 1946), and
we ascertained an additional family (F2) with two af-
fected members (fig. 1b). Most of the patients live within
a 160-km radius in a geographically isolated region of
northeastern Newfoundland, suggesting the possibility
of a founder effect. With institutional review board ap-
proval and informed consent, we collected DNA samples
from 57 individuals, including one deceased but diag-
nosed affected individual and seven living persons di-
agnosed with HSAN type II on the basis of quantitative
sensory and autonomic testing and, when necessary, sen-
sory and motor nerve conduction studies. In families F1
and F2, the mode of inheritance appeared autosomal
recessive, as reported for other families with HSAN type
II (Ohta et al. 1973; Kondo and Horikawa 1974). Sub-
sequently, we obtained samples from a group of French
Canadians consisting of two affected sisters (F3-301 and
F3-302) and one affected individual (F4-301) with no
close family ties to the affected F3 sisters from a larger
cohort of HSAN type II families in French Canada (Rod-
dier et al. 2003). Finally, DNA was obtained from two
affected sisters (F5-301 and F5-302) who were diag-
nosed with HSAN type II in Nova Scotia and whose
parents were consanguineous but of uncertain ethnic or-
igin (Murray 1973; Davar et al. 1996).
We performed a complete 5-cM genome scan of New-
foundland families F1 and F2 using 763 autosomal and
48 X-chromosomal markers. Two-point linkage analysis
identified 10 markers in eight chromosomal regions with
the sum of two-point LOD scores 12.0 (data not shown).
One such marker (D12S352) mapping to the telomere
of 12p showed extensive though incomplete allele shar-
ing in the affected individuals (fig. 2a), with an additive
2-point LOD score of 2.64 at zero recombination, sug-
gesting linkage to the 12p13 region. Additional micro-
satellite markers in this region revealed that all seven
living affected individuals in both families were homo-
zygous for a common haplotype spanning 1.2 Mb with
a highly significant LOD score (table 1, fig. 2a). The
additional markers defined recombination events con-
sistent with the incomplete allele sharing observed in the
genome scan. Subsequently, we genotyped affected in-
dividuals from the two French Canadian families (F3
and F4). Haplotype data were consistent with linkage
to this chromosomal region and suggested that there may
be two distinct mutations in the French Canadian pop-
ulation (fig. 2a). A recombination event in one of the
sisters in F3 reduced the size of the candidate region to
between 1.040 and 1.057 Mb (fig. 2).
A total of seven annotated transcripts were identified
in the candidate region from the completed human ge-
nomic assembly (fig. 2b). These included PRKWNK1,
Figure 1 Phenotype of HSAN type II and pedigrees for large Newfoundland families described in this study. a, Examples of clinical
presentations. Patients in these families suffer from loss of touch and pain sensation leading to ulceration, infection, muscle atrophy, and
amputation of digits. b, Partial pedigrees of families F1 and F2. Squares and circles represent males and females, respectively. Blackened symbols
indicate individuals with HSAN type II. Unblackened symbols indicate individuals normal by clinical examination, and symbols with a question
mark indicate individuals who have not been examined. Diagonal slashes indicate deceased individuals. All examined individuals were included
in the genome scan or the subsequent fine mapping.
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Figure 2 Haplotype analysis and candidate region. a, Haplotypes were constructed for all genotyped individuals in families F1 and F2,
but here only affected haplotypes are shown. GENEHUNTER v2.1_r2 beta (Kruglyak et al. 1996; Kruglyak and Lander 1998) was used to
construct haplotypes on pedigree sections, which were then manually combined. Haplotypes are designated with pedigree (F) number, individual
number, and chromosome (a or b) number. The three different haplotype groups bearing causal mutations are numbered 1–3. Allele sizes are
given in bp. Markers are indicated at the top, with their physical distances from the telomere given in kb on the basis of the July 2003 build
34 human genome assembly and their genetic positions, according to the deCODE map. Portions of haplotypes encompassing the HSN2 locus
are boxed. Haplotypes for F1 and F2 are phased, except for F1–122/124, which was inferred from genotypes in parent F1-122 and deceased
offspring F1-124. Phasing of F3-301 and F3-302 was inferred on the basis of allele sharing with a region of homozygosity in F4-301. Recom-
bination breakpoints in the shared haplotype in individuals F1-171 and F1-124 placed the HSAN II locus between markers CA1AC0021054
and D12S1642. Affected French Canadian samples were subsequently genotyped for markers in this region. A recombination event in one of
the sisters in F3 positioned the centromeric boundary at marker CA1AC005183. b, Physical map of the HSAN II candidate region, showing
markers used in the genetic analysis and candidate genes represented as unblackened arrows (derived from UCSC genome annotation). The
arrows indicate the direction of transcription for each gene. The distances are given in kb from the telomere on the basis of the July 2003 build
34 human genome assembly. The HSN2 gene is indicated by a blackened arrow. To identify unannotated conserved ORFs, the human genomic
sequence representing the entire HSAN II candidate interval (∼1.0 Mb) was downloaded with case toggled to highlight the mouse translated
BLAT track (which represents regions showing significant protein homology between human and mouse). These sequences were assembled into
a contig, to which all exons of previously identified candidate genes were added. All sequences were manipulated using DNASTAR software.
The contig was scanned for novel conserved fragments (180% conservation over 1100 bp). This identified 64 novel fragments, which were then
tested for functional homology using (1) BLASTn against the nr database, (2) BLASTn against the dbEST, and (3) BLASTx against the nr
database available from the NCBI Web site. The HSN2 gene was, by a substantial margin, the most highly conserved and the longest ORF
among these fragments. It should be noted that various gene-prediction algorithms—such as ECgene, Geneid, SGP, and Twinscan—also predict
the HSN2 ORF, in whole or in part, either as a separate exon or as a potential alternative exon of the PRKWNK1 gene (for which there is no
evidence among mammalian ESTs).
RAD52, ELKS, FBXL14, WNT5B, and portions of
ADIPOR2 and NINJ2. The syntenic region in the mouse
genome is ∼800 kb in size, located on chromosome 6,
and conserves this gene order. All seven annotated tran-
scripts in the candidate region were sequenced in samples
from affected patients, but no causative mutations were
observed. A more exhaustive search for unannotated
genes was therefore conducted on the basis of conserved
homologies between the human and mouse genome as-
semblies, together with a requirement for an extended
ORF of 1100 amino acids. This search identified a novel
unannotated yet well-conserved 434–amino acid ORF
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Table 1
Linkage Analysis in Region 12p
MARKER
LOD FOR FAMILY AND RECOMBINATION FRACTION (V)
POSITION F1 F2 F1 and F2
NCBI Build 34
(kb)
deCODE Map
(cM) .00 .01 .05 .10 Max .00 .01 .05 .10 Max .00 .01 .05 .10 Max
GGAT2AC007406 197 .00 .33 .88 1.06 1.06 4.14 1.04 .41 .18 .01 4.14 .71 .48 .88 .90
D12S352 531 .00 3.40 3.49 3.45 3.14 3.49 .84 .82 .72 .59 .84 4.24 4.31 4.16 3.73 4.31
GAAA2AC021054 591 2.84 2.92 2.85 2.52 2.92 .37 .37 .33 .28 .37 3.22 3.29 3.18 2.80 3.29
GAAA1AC021054 650 4.69 4.73 4.57 4.14 4.73 .00 .00 .00 .00 .00 4.69 4.73 4.57 4.14 4.73
CA1AC021054 652 2.94 3.02 2.95 2.63 3.02 .37 .37 .33 .28 .37 3.32 3.39 3.28 2.91 3.39
CA2AC021054 656 5.10 5.07 4.81 4.36 5.10 .97 .94 .82 .67 .97 6.07 6.01 5.63 5.03 6.07
GAAA3AC021054 701 2.54 2.56 2.54 2.37 2.56 .64 .41 .07 .05 .09 1.91 2.15 2.46 2.42 2.46
D12S341 719 5.10 4.98 4.48 3.86 5.10 .08 .08 .07 .06 .08 5.18 5.06 4.55 3.92 5.18
CA1AC004765 756 5.50 5.37 4.83 4.16 5.50 .11 .13 .17 .18 .18 5.61 5.50 5.00 4.34 5.61
CA2AC004765 771 .95 .93 .82 .70 .95 .00 .00 .00 .00 .00 .95 .92 .82 .70 .95
D12S94 781 7.26 7.12 6.54 5.80 7.26 .00 .00 .00 .00 .00 7.26 7.12 6.54 5.80 7.26
D12S91 817 1.03 5.08 4.96 4.45 3.81 5.08 .37 .37 .33 .28 .37 5.46 5.32 4.78 4.09 5.46
CA1AC004803 876 4.26 4.14 3.69 3.12 4.26 .97 .94 .82 .67 .97 5.22 5.08 4.50 3.79 5.22
D12S389 984 1.69 3.88 3.80 3.46 2.99 3.88 .37 .37 .33 .28 .37 4.25 4.17 3.78 3.27 4.25
A1AC004803 963 .66 .63 .53 .41 .66 .37 .37 .33 .28 .37 1.03 .99 .86 .69 1.03
D12S1285 1404 6.54 6.41 5.88 5.20 6.54 .97 .94 .82 .67 .97 7.51 7.35 6.70 5.86 7.51
D12S1608 1629 3.65 4.80 4.68 4.19 3.58 4.80 .97 .94 .82 .67 .97 5.77 5.61 5.00 4.24 5.77
CA1AC005182 1631 6.56 6.43 5.88 5.17 6.56 .97 .94 .82 .67 .97 7.53 7.36 6.69 5.84 7.53
D12S1656 1677 4.12 3.12 3.02 2.66 2.21 3.12 .97 .94 .82 .67 .97 4.08 3.96 3.47 2.88 4.08
CA1AC005183 1691 2.14 2.07 1.82 1.51 2.14 .97 .94 .82 .67 .97 3.10 3.01 2.64 2.18 3.10
CA3AC005343 1744 3.73 3.62 3.20 2.68 3.73 .97 .94 .82 .67 .97 4.69 4.56 4.02 3.35 4.69
CA2AC005343 1781 5.98 5.97 5.72 5.21 5.98 .97 .94 .82 .67 .97 6.95 6.91 6.53 5.87 6.95
CA1AC005343 1783 7.48 7.34 6.77 6.03 7.48 .97 .94 .82 .67 .97 8.44 8.27 7.58 6.70 8.44
CA1AC090840 1876 6.82 6.68 6.12 5.41 6.82 .97 .94 .82 .67 .97 7.78 7.62 6.94 6.07 7.78
D12S1642 1904 1.52 1.48 1.31 1.10 1.52 .08 .08 .07 .06 .08 1.60 1.56 1.38 1.15 1.60
CA2AC005342 1973 6.53 6.40 5.86 5.17 6.53 .97 .94 .82 .67 .97 7.50 7.33 6.67 5.83 7.50
CA1AC005342 2036 5.49 5.44 5.13 4.62 5.49 .97 .94 .82 .67 .97 6.46 6.38 5.95 5.29 6.46
D12S100 2047 4.76 6.50 6.37 5.83 5.14 6.50 .97 .94 .82 .67 .97 7.47 7.30 6.65 5.81 7.47
D12S1689 2205 2.89 2.80 2.46 2.05 2.89 .08 .08 .07 .06 .08 2.97 2.89 2.54 2.11 2.97
D12S1694 2256 4.76 7.46 7.32 6.73 5.98 7.46 .97 .94 .82 .67 .97 8.43 8.25 7.55 6.65 8.43
D12S1615 2640 5.64 3.67 3.87 4.03 3.81 4.03 .00 .00 .00 .00 .00 3.67 3.87 4.03 3.81 4.03
D12S1626 3166 7.07 2.88 2.97 2.93 2.62 2.97 .97 .94 .82 .67 .97 3.84 3.91 3.74 3.29 3.91
D12S1652 3583 9.04 3.51 3.58 3.46 3.07 3.58 .97 .94 .82 .67 .97 4.48 4.52 4.28 3.73 4.52
D12S1725 4316 13.14 1.14 .76 .11 .16 .23 4.35 1.16 .51 .27 .00 5.49 1.92 .62 .11 .14
D12S1624 4581 1.56 1.22 .50 .11 .13 4.50 1.06 .46 .26 .00 6.06 2.28 .95 .37 .05
D12S314 4839 13.96 1.24 .82 .08 .25 .37 4.50 1.06 .46 .26 .00 5.74 1.88 .54 .01 .25
D12S93 5201 15.00 1.22 .91 .39 .18 .00 .21 .20 .16 .10 .00 1.43 1.11 .55 .28 .00
D12S99 5435 15.20 .83 .51 .05 .25 .25 5.54 2.85 1.49 .93 .00 6.37 3.36 1.43 .67 .00
NOTE.—Samples from 15 family members from F1 and 7 family members from F2, including a total of seven living affected individuals from Newfoundland, were genome scanned. Genomic
DNA was extracted from blood samples using a standard salt-extraction method. DNA was also obtained from tissue samples of one deceased individual in F1, previously diagnosed with
HSAN type II. We carried out a 5-cM whole-genome screen using the LMS2 HD-5 microsatellite screening set (Applied Biosystems) and Prism 3100 and 3700 Genetic Analyzers running
GeneMapper software (Applied Biosystems). For fine mapping, we analyzed an additional 16 Genethon markers and 1 CHLC marker (derived from NCBI, GDB, and Marshfield databases),
and designed 18 novel markers containing short tandem repeats on the basis of publicly available genomic sequences. Genome-scan markers are indicated in boldface italics in the table. Primer
sequences for all markers are indicated in table A1 (online only); map locations are described using the deCODE genetic maps (Kong et al. 2002) and physical locations are based on the July
2003 build 34 genome assembly. Mendelian inheritance of alleles was verified using the PedCheck program (O’Connell and Weeks 1998). We performed pairwise linkage analysis on the F1
and F2 pedigrees using MLINK from the FASTLINK v4.1p program (Cottingham et al. 1993; Schaffer et al. 1994) and allowing for known pedigree consanguinity loops. We calculated
maximum pairwise cumulative LOD scores as the maximum LOD over tested V of the sum of V-specific LODs for the F1 and F2 pedigrees. We chose to not carry out multipoint linkage
since pairwise results were sufficiently convincing and we wished to retain the consanguinity information of F1 for linkage. We set equal marker allele frequencies for the genomewide linkage
scan. For the follow-up linkage analysis at 12p13, allele frequencies were estimated using 16 chromosomes from 8 unrelated individuals from the Newfoundland population, as well as 8
untransmitted chromosomes from F3 and F4 (F3-9, F3-10, F4-37, F4-38, F4-112, F4-122, F4-371). Frequencies were estimated using allele counting. Unobserved alleles were set to 0.02
frequency, and all frequencies were proportionally transformed to sum to 1. Two consanguineous loops of F1 were broken at individuals 15 and 708. We used an autosomal recessive model
with a disease allele frequency of 0.007, penetrance of 0.975, and phenocopy rate of 0.000003, as calculated from the disease prevalence in the population. Linkage tests using equal allele
frequencies were carried out in parallel for the fine-mapping data presented in the table. We believe that using the estimated allele frequencies from the Newfoundland population does provide
more accurate LOD score estimates; however, LOD scores calculated using equal allele frequencies provided significant results as well, with a maximum LOD of 5.88 at D12S1285.
located within intron 8 of the PRKWNK1 gene (fig. 2b).
Sequencing of samples containing the three linked hap-
lotypes revealed that this ORF harbored three different
truncating mutations in the affected patients (figs. 3, 4a).
One mutation was found in homozygous state in the
affected Newfoundland subjects. This mutation was
found only in Newfoundland and cosegregated perfectly
with the presumptive affected haplotype in families F1
and F2. The other two mutations found in the French
Canadian families were in either the homozygous or the
compound heterozygous state, consistent with the hap-
lotypes in F3 and F4. Subsequent work has shown that,
in all identified French Canadian patients, mutations co-
segregate in either the homozygous or the compound
heterozygous state, consistent with haplotype analysis
(B.B., unpublished observations). One of these muta-
tions was also homozygous in both Nova Scotia F5
samples.
None of these three mutations were found in 192 nor-
mal chromosomes of European descent, in 180 Coriell
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Figure 3 Mutations in the HSN2 gene in affected individuals. To screen the HSN2 ORF for mutations, three separate amplicons were
designed (for primers, see appendix A [online only]) using PrimerSelect (DNASTAR) and were purchased from BioCorp. Amplified products
were sequenced at the Montreal Genome Centre sequencing facility. Sequence traces were aligned using SeqManII (DNASTAR) and were
inspected visually for mutations. Each panel displays a sequencing trace from a normal control (above) and from an affected individual (below)
according to the following: a, Homozygous c.594delA mutation in patient F1-70 from Newfoundland, causing a frameshift in codon 198 leading
to premature truncation to a 206-aa peptide. This mutation cosegregated perfectly with the disease in the F1 and F2 families from Newfoundland
as predicted from the haplotype analysis. b, Homozygous c.918–919insA mutation in patient F5-301 from Nova Scotia, causing a frameshift
in codon 307 and truncation to a 318-aa peptide. Both Nova Scotia siblings shared this mutation, which was also heterozygous in the French
Canadian F3 samples. c, Homozygous c.943CrT nonsense mutation in French Canadian patient F4-301, changing codon 315 (CAG, encoding
glutamine) to a TAG stop codon, and truncating the protein to 314 aa. This mutation was also heterozygous in the F3 samples. All sequence
traces are from the forward strand. To genotype each of the three mutations in additional family members and population controls, we used
PCR-RFLP or capillary electrophoresis analysis (details of mutation detection sequencing and genotyping in appendix A [online only]).
control chromosomes of mixed ethnicity, or in any pub-
lic sequence databases. The clustering of three different
disrupting mutations within a small conserved ORF in
five formally unrelated HSAN type II families strongly
supports the conclusion that these mutations are the di-
rect cause of the HSAN type II phenotype. We therefore
propose that the “HSN2” gene encodes this novel ORF;
this nomenclature has been accepted by HUGO.
To confirm the comparative genomic analysis, addi-
tional HSN2 gene orthologs from rat and zebrafish, as
well as mouse, were identified by a BLAST search of
their respective genomic assemblies (fig. 4a). Each HSN2
ortholog mapped within the conserved intron of the
PRKWNK1 ortholog and was encoded on the same
strand as PRKWNK1. To verify the presumptive struc-
ture of the HSN2 gene, we closely examined ESTs over-
lapping or mapping near the ORF. As such, a number
of human cDNA clones, derived from a variety of adult
and fetal tissues, were identified from genome databases.
In one of these cDNA clones containing a portion of the
ORF (accession number BF695311, corresponding to
IMAGE:4244848 cloned from skeletal muscle, pur-
chased from Research Genetics and resequenced by us),
a long polyA tail was detected just downstream of an
AATAAA polyA addition signal; however, the clone was
incomplete at the 5′ end. A placentally derived pig-cDNA
clone with similarity at the protein level (corresponding
to the partial sequence in accession number BI399422,
originally identified through the Gene Discovery Pro-
gram for Functional Genomics in Pig Reproduction) was
obtained from Open Biosystems, and the insert was se-
quenced. This cDNA clone encodes the entire predicted
HSN2 peptide (fig. 4a), plus 475 bp of 5′-UTR, 561 bp
of 3′-UTR, and a polyA tail at a site aligning with the
human polyA site (fig. 4b). Thus, the pig cDNA may
represent a nearly full-length HSN2 transcript. HSN2
transcripts could not be detected by northern blotting
using an adult human tissue panel (Clontech 12-lane
human 636818 including brain, heart, skeletal muscle,
colon, thymus, spleen, kidney, liver, small intestine, pla-
centa, lung, and peripheral blood leukocyte), suggesting
that the gene may be expressed at very low levels. RT-
PCR experiments using cDNA from human fibroblast,
thyroid, liver, testes, small intestine, adrenal gland, brain,
and dorsal root ganglion were similarly inconclusive;
these are complicated by the absence of a splice junction
and thus potential contamination with either trace ge-
nomic DNA or incompletely processed PRKWNK1 tran-
scripts. Further analysis will be required to define the
exact transcript structure and expression pattern of
HSN2. The low level and distribution of expression sug-
gested by ESTs is consistent with a gene specifically ex-
pressed from peripheral sensory neurons or supporting
cells, which are distributed throughout many organs and
tissues but constitute only a very small percentage of any
given tissue’s mass.
These observations suggest that the HSN2 gene spans
∼3 kb and consists of a single exon nested within an
intron of the PRKWNK1 gene and transcribed from the
same strand. The structure of the HSN2 gene is thus
unusual and may be the first example of a causative
mutation in a human gene mapping within the intron
of another gene. Single exon genes are somewhat atyp-
ical but well-documented; moreover, the HSN2 sequence
is unique in each genome assembly examined, which
indicates that it is not a pseudogene. The PRKWNK1
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Figure 4 Alignment of predicted HSN2 peptide sequences for vertebrate orthologs. a, The conserved HSN2 ORF was identified from the
genomic assemblies of human, mouse, rat, and zebrafish (Zfish) and from the pig cDNA clone. BLAST searches were done through the NCBI
Web site. Genomic sequences for HSN2 orthologs were identified within GenBank sequence files AC004765 (human), AC106932 and AC106348
(rat), AC113092 (mouse), and BX321885 (zebrafish). Prosite searches were done through the EBI server. For the predicted peptide sequence
alignment, sequences were aligned using Clustal 1.8, available from the BCM Search Launcher Web site. Aligned sequences then were shaded
using BOXSHADE. Functional bioinformatics analysis was performed using SignalP. Conserved residues are shaded. Residues are numbered
from the most upstream start ATG. Asterisks (*) above N-terminal residues indicate potential initiating methionines; asterisks at the C-termini
indicate the stop codons. The signal peptide and predicted cleavage residue are indicated at the N-terminus. Positions of causative mutations
in human populations are indicated. b, Alignment of 3′ ends of resequenced human and pig cDNA clones with the human genomic sequence,
showing conservation of polyadenylation sites. The putative polyadenylation signal is shown above the aligned sequences.
gene is expressed in polarized epithelia in a number of
tissues of patients with hypertension, and dominant mu-
tations are thought to disrupt the regulation of epithelial
Cl flux, leading to pseudohypoaldosteronism type IIC
(MIM 605232) (Wilson et al. 2001; Choate et al. 2003).
There is no overlap in observed phenotypes between
HSAN type II and pseudohypoaldosteronism, support-
ing the notion that transcription of these two genes may
be differentially regulated.
Bioinformatic analysis of the predicted HSN2 amino
acid sequence identifies a potential signal peptide motif
at the amino terminus of the mammalian proteins (fig.
4a). However, there are three methionines closely spaced
at the N-terminus of the ORF, and the occurrence of
this signal peptide thus depends on which of these is the
true initiating methionine. If that is the case, then HSN2
may conceivably be a secreted protein and possibly a
novel neurotrophic factor. The NTRK1 gene underlying
HSAN type IV is a known receptor of a nerve growth
factor; it is conceivable that this receptor may also bind
a secreted HSN2 peptide, although there is no obvious
sequence similarity between HSN2 and any known
protein.
Identification of the hereditary basis of HSAN type II
represents a key advance in the diagnosis and manage-
ment of this and other peripheral neuropathies. HSN2
represents the fifth identified gene that when mutated
results in a sensory and autonomic neuropathy pheno-
type. There is no obvious unifying theme among all these
genes, which include a biosynthetic enzyme in a lipid
pathway (HSAN type I/SPTLC1) (Bejaoui et al. 2001;
Dawkins et al. 2001), a presumptive transcriptional reg-
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ulator (HSAN type III/IKBKAP) (Anderson et al. 2001;
Slaugenhaupt et al. 2001), a nerve growth factor recep-
tor (HSAN type IV/NTRK1) (Mardy et al. 1999), a nerve
growth factor (NGFB) (Einarsdottir et al. 2004), and a
novel protein (HSAN type II/HSN2). If HSN2 is a novel
growth factor, then, by virtue of its association with
peripheral neuropathy, it may conceivably act via the
NTRK1 gene, and IKBKAP could potentially play a role
in a subsequent signal transduction pathway. There are
numerous clinical differences among these disorders,
however, as well as potential differences in neuropa-
thology. Further work will be required to resolve this
question and to elucidate the role of these genes in neu-
ronal development and function.
Given that the HSAN type II phenotype is character-
ized by absence of pain sensations owing to loss of fibers
in the peripheral nervous system (Murray 1973; Dyck
1993), the HSN2 protein may play a role in the devel-
opment or maintenance of peripheral sensory neurons
or their supporting cells. The pathology of HSAN type
II resembles in many respects that of diabetic neurop-
athy. Affecting as many as 50% of diabetic patients,
initial symptoms of peripheral diabetic neuropathy (tin-
gling, burning, and numbness in feet) mimic the pre-
senting features of HSAN type II. In addition, sural nerve
biopsy shows, in both diseases, a reduction in myelinated
and unmyelinated nerve fibers (Llewelyn et al. 1991;
Zorrilla Hernandez et al. 1994; Yasuda et al. 2003). It
is possible that a therapeutic targeted to upregulate
HSN2 or a protein therapeutic derived from HSN2 could
be used to prevent the nerve-degeneration features of
diabetic neuropathy, which currently has no specific
treatment modality. In addition to diabetic neuropathy,
other neuropathies that could potentially benefit from
an HSN2 targeted therapeutic include HIV- and Hepa-
titis C-related neuropathies (Polydefkis et al. 2002; Lu-
ciano et al. 2003) and other less prevalent but significant
metabolic and mitochondrial disorders.
In the literature, there are additional reports of phe-
notypes resembling HSAN type II (Ferriere et al. 1992;
Basu et al. 2002; Krishna Kumar et al. 2002; Sanvito et
al. 2003), and it is now feasible to determine whether
those conditions are because of mutations in the HSN2
gene or the result of additional genetic determinants.
Furthermore, with the reported higher incidence of
HSAN type II in French Canada, Nova Scotia, and New-
foundland, there is potentially a high carrier rate in parts
of eastern Canada. Because of the severe disability of
the disease and the early age at onset, carrier testing of
HSN2 and genetic counseling is now a feasible option
for at-risk relatives of affected individuals. It may also
be possible to examine whether carriers are at increased
risk of neuropathic complications secondary to other
diseases, such as diabetes.
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